Fourth Quarter and Full Year 2025 Revenue and Adjusted EBITDA Results In-line with Previous Guidance Pharma Direct Revenue Beats Previous Outlook with Over 40% Year-Over-Year Growth for 2025 SANTA MONICA, Calif. -- (February 25, 2026) -- GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading platform for medication savings in the U.S., has released its financial results for the fourth quarter and full year of 2025. Fourth Quarter 2025 Highlights Full Year 2025 High ...